India, Oct. 13 -- Lupin Limited will present findings from its Phase 1a clinical trial of LNP3693, a STING agonist, at the ESMO Congress 2025 in Berlin, Germany, scheduled from October 17–21, 2025. The presentation, titled "A Phase 1 Dose Escalation Study of LNP3693 (STING Agonist) in Patients with Advanced or Metastatic Solid Tumors & Lymphoma", will be featured in the Investigational Immunotherapy session (Presentation Number 1553P) on October 19, 2025, from 09:00 to 17:00 CEST.
The data will offer insights into the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of LNP3693 in patients with solid tumors. LNP3693 is an investigational parenteral STING agonist under development by Lupin.
Commenting on...